Cat. No. | Product name | CAS No. |
DCC4765 |
Sklb-329
Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase |
|
DCC4766 |
Sklb-677
Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML |
|
DCC4767 |
Sklb70326
Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells |
1257317-77-3 |
DCC4768 |
Skog102
Novel inhibitor of OLIG2 in glioblastoma |
1983927-39-4 |
DCC4769 |
skp Inhibitor C16
Specific Inhibitor of Skp2-Mediated p27 Degradation |
432016-45-0 |
DCC4770 |
skp Inhibitor C20
Specific Inhibitor of Skp2-Mediated p27 Degradation |
329918-37-8 |
DCC4771 |
Skp2 Inhibitor C2
First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation |
428844-86-4 |
DCC4772 |
Sl-1-73
Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
2000199-44-8 |
DCC4773 |
Sl-3-19
Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
2000199-45-9 |
DCC4774 |
Sl-651498
Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits. |
205881-86-3 |
DCC4775 |
Sl910102
Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19 |
144756-71-8 |
DCC4776 |
Slec-8
Potential synthetic lethal lead, targeting E-cadherin-deficient cells |
|
DCC4777 |
Slk/stk10-in-31
Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10) |
|
DCC4778 |
Sll-039
Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283) |
|
DCC4779 |
Slm6071469
Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity |
|
DCC4780 |
Slp120701
Novel SphK2-selective inhibitor with improved half-life to 8 h in mice |
1449768-46-0 |
DCC4781 |
Slp7111228
Novel selective SphK1 inhibitor |
1449768-48-2 |
DCC4782 |
Slr080811
Novel SphK2-selective inhibitor |
1449768-35-7 |
DCC4783 |
Slupp-225
Novel efflux pump inhibitor (EPI) |
|
DCC4784 |
Slupp-417
Novel efflux pump inhibitor (EPI) |
|
DCC4785 |
Sm-130686
Potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue |
259667-25-9 |
DCC4786 |
Sm-131
Novel Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic |
874270-41-4 |
DCC4787 |
Sm-337
Non-peptidic Smac mimetic, binding to XIAP, cIAP-1 and cIAP-2 proteins with higher affinities in cell growth inhibition in the MDA-MB-231 cell line |
1071992-61-4 |
DCC4788 |
Sm4487
Novel potent and selective inhibitor of galactokinase (GALK1) |
|
DCC4789 |
Sma-12b
Novel inhibitor of IL-1 |
1496553-39-9 |
DCC4790 |
Smac127
Proapoptotic and anti-inflammatory agent, inducing apoptosis by inhibiting apoptosis proteins (IAPs) |
|
DCC4791 |
Smapp1
Novel activator of PP1, inducing HIV-1 transcription, reactivation of latent HIV-1 in chronically infected cells, and CDK9 phosphorylation |
327081-00-5 |
DCC4792 |
Smart-h
Potent inhibitor of microtubule polymerization |
1135797-91-9 |
DCC4793 |
Smart-oh
Potent inhibitor of microtubule polymerization |
1311195-76-2 |
DCC4794 |
Smases D Inhibitor-1
Novel inhibitor of Loxosceles sphingomyelinases D (SMases D) |
849020-48-0 |
DCC4795 |
Smases D Inhibitor-5
Novel inhibitor of Loxosceles sphingomyelinases D (SMases D) |
|
DCC4796 |
Smcy 5.5
Fluorogenic fluorescent probe for imaging lipid droplets; suitable for use with two-photon microscopy |
2417507-09-4 |
DCC4797 |
Smdc818909
Novel Allosteric Inhibitor of p97 |
1147823-21-9 |
DCC4798 |
Smer10
Novel enhancer of the clearance of mutant aggregate-prone proteins by autophagy in mammalian cell models of Huntington's and Parkinson's disease, independent of rapamycin |
221238-83-1 |
DCC4799 |
S-mgb-234 Bis-tfa Salt
Novel strathclyde minor groove binder (S-MGB), curing animal African trypanosomiasis (AAT) |
1970223-54-1 |
DCC4800 |
smip001
Novel enhancer of the cyclin-dependent kinase (CDK) inhibitor p27(Kip) |
397872-93-4 |
DCC4801 |
Smip2.1
Novel TLR2 agonist, promoting cross-presentation by mouse and human antigen presenting cells |
|
DCC4802 |
Smk-17
Novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor |
765958-29-0 |
DCC4803 |
Sml-10-70-1
Selective, direct-acting covalent inhibitor of the K-Ras G12C mutant relative to wild-type Ras |
1536470-98-0 |
DCC4804 |
Sml-8-73-1
Novel Active Site Inhibitor of Oncogenic K-Ras G12C |
|
DCC4805 |
Smn2-stablizer-27
Novel Stablizer of Survival of Motor Neuron 2 (SMN2) , Post-Translationally Stablizing SMN Protein for the Treatment of Spinal Muscular Atrophy (SMA) |
|
DCC4806 |
Smn-c5
Novel specific splicing enhancer, targeting RNA for a specific splicing correction, recognizing the interface between U1 snRNP and the SMN2 E7 5ʹ SS, promoting the U1-C zinc finger RNA duplex binding activity |
|
DCC4807 |
Smt022357
Second-generation modulator of utrophin, increasing utrophin expression in skeletal, respiratory and cardiac muscles |
|
DCC4808 |
Smtp-7
Novel dual inhibitor of thrombolysis and soluble epoxide hydrolase |
273379-50-9 |
DCC4809 |
Smurf1 Inhibitor 1
Novel Smurf1 inhibitor, promoting bone formation in mouse models of distinctive age-related osteoporosis |
136068-42-3 |
DCC4810 |
Smu-z1
Novel potent TLR1/2 Specific Agonist, Suppressing Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes |
|
DCC4811 |
Sn16713
Selective ligand of GC-rich sequences in DNA |
88476-68-0 |
DCC4812 |
Sn-28049
Novel potent DNA-binding topoisomerase II-directed antitumor agent. |
492472-30-7 |
DCC4813 |
Sn34037
Novel specific inhibitor of Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) |
1548116-54-6 |
DCC4814 |
Sn-38 Prodrug 3c
Novel Bioorthogonal Prodrug of SN-38 with Fast Reaction Kinetics and High Releasing Efficiency In Vivo |
|
DCC4815 |
Snap-398299
Potent and selective GAL3 antagonist |
903878-06-8 |
DCC4816 |
Snap-5089
Highly selective alpha1A-adrenoceptor antagonist |
157066-77-8 |
DCC4817 |
Sniper(abl)-38
Specific and Nongenetic IAP-dependent Protein Eraser (SNIPER), acting as a protein degradation inducer of oncogenic BCR-ABL protein |
|
DCC4818 |
Sniper(brd4)-1
Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Eraser (SNIPER), acting as a a protein degradation inducer of bromodomain-containing protein 4 (BRD4) |
|
DCC4819 |
Sniper(ch6)
Novel fused proteins degrader of the His-tagged CRABP-II and Smad2 in cells |
|
DCC4820 |
Sniper(crabp)-11
Novel potent degrader of the mitochondrial CRABP-II protein |
1384275-50-6 |
DCC4821 |
Sniper(er)-87
Novel potent and selective degrader of the ERα protein |
2222354-91-6 |
DCC4822 |
Sniper(pde4)-9
Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Eraser (SNIPER), acting as a a protein degradation inducer of phosphodiesterase-4 (PDE4) |
|
DCC4823 |
Snri-h05
Novel potent serotonin and noradrenaline reuptake inhibitor (SNRI) with moderate 5-HT2A antagonist activity for anti-depression |
|
DCC4824 |
sns-oh
Inducer of apoptosis in neuroblastoma cells through inhibition of AKT signaling pathway |
1354834-09-5 |
DCC4825 |
Snu-bp
Novel agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines, potentiating interleukin-4-induced arginase-1 expression, promoting microglial polarization toward to an M2 anti-inflammatory phenotype |
1621513-98-1 |
DCC4826 |
Snx2-1-108
Highly selective inhibitor of CDK8 and its isoform CDK19 |
1366002-73-4 |
DCC4827 |
So1989
Novel macrophage modulator, inhibiting inflammation and M1 polarization of macrophages, restoring the balance between M1-polarized and M2-polarized macrophages in high fat diets (HFD)-induced obese mice resulting in the improvement of adipose inflammation |
|
DCC4828 |
soblidotin
Inhibitor of tubulin polymerization, resulting in cell cycle arrest and induction of apoptosis |
149606-27-9 |
DCC4829 |
Sobuzoxane
Orally available active prodrug of ICRF-154, interferring with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition |
98631-95-9 |
DCC4830 |
Sod1-derlin-1 Inhibitor 56-20
Novel potent inhibitor of SOD1-Derlin-1 interaction |
840461-03-2 |
DCC4831 |
Sod1-derlin-1 Inhibitor 56-26
Novel potent inhibitor of SOD1-Derlin-1 interaction |
489402-79-1 |
DCC4832 |
Sodelglitazar
PPARdelta receptor agonist |
447406-78-2 |
DCC4833 |
Sodium Dehydrocholate
Hepatoprotective and choleretic agent |
145-41-5 |
DCC4834 |
Sodium Oxybate
Narcolepsy agent, being used to treat catalepse and daytime sleepiness in patients with narcolepsy |
502-85-2 |
DCC4835 |
Solanidine
Natural tumor antagonistic steroidal alkaloid, inducing typical cellular apoptotic hallmarks and cell cycle blockage at S-G2/M phase, activating nuclear import of DFF-40 mediated nucleosomal disruption and cell demise |
80-78-4 |
DCC4836 |
Solimastat
Novel oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI), being >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-alpha |
226072-63-5 |
DCC4837 |
Somapacitan
Novel long-acting, reversible albumin-binding growth hormone (GH) derivative for treatment of growth hormone dificiency |
1338578-34-9 |
DCC4838 |
Somatoprim
Unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reducing GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. |
252845-37-7 |
DCC4839 |
Somcl-668
Novel potent and selective allosteric modulator of sigma-1 receptor |
|
DCC4840 |
Somcl-863
Novel, selective and orally bioavailable c-Met inhibitor, exhibiting antitumor activity both in vitro and in vivo |
1452310-87-0 |
DCC4841 |
Sonedenoson
A2A adenosine receptor agonist |
131865-88-8 |
DCC4842 |
Sophoradin
Natural analgesic, antipyretic, anti-inflammatory, and anti-tumor agent |
23057-54-7 |
DCC4843 |
Sophorafavanone A
Inhibitor of constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase |
87893-18-3 |
DCC4844 |
Sophoraflavanone B
Natural inhibitor of the Kv1.3 channels in a concentration-dependent manner |
68682-02-0 |
DCC4845 |
soraphinol A
Human norepinephrine transporter blocker |
1006373-58-5 |
DCC4846 |
sori-20041
DAT modulator, being unique in affecting substrate uptake without impacting efflux |
488082-05-9 |
DCC4847 |
sori-9804
Novel partial inhibitor of amphetamine-induced dopamine release |
434326-29-1 |
DCC4848 |
Sortin3 Maleate
Sorting inhibitor, blocking Vps16 function, one protein in the class C tethering complex, and increasing aflatoxin synthesis and export |
|
DCC4849 |
Spam (signal Peptide-based Affinity Maturated Ligand)
Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1) |
|
DCC4850 |
spb03924
Novel telomerase inhibitor |
263766-82-1 |
DCC4851 |
SPB08007
0 |
|
DCC4852 |
Spd-2-am
Novel photo-controllable hydrogen sulfide donor applicable in live cells |
|
DCC4853 |
Spectinamide-1599
Novel anti-tuberculosis agent against intracellular Mycobacterium tuberculosis |
|
DCC4854 |
Spectinomycin Dihydrochloride
Antibiotic, binding to the bacterial 30S ribosomal subunit, interfering with the initiation of protein synthesis and with proper protein elongation and leading to bacterial cell death |
21736-83-4 |
DCC4855 |
Spi-1865
Novel gamma-secretase modulator |
|
DCC4856 |
Spirohydantoin-21
Novel selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase |
|
DCC4857 |
Spirooxindole 1a
Novel p53 Stabilizer for Brain Cell Differentiation |
|
DCC4858 |
Spiroxamine
Sterol Biosynthesis Inhibitor, Fungicide |
118134-30-8 |
DCC4859 |
Spla2 Inhibitor Pyr-1
Novel potent sPLA2 inhibitor, selectively targeting hGIIA and hGIID |
|
DCC4860 |
Spmtrien
Novel isosteric charge-deficient spermine analogue |
|
DCC4861 |
spongiacidin C
USP7 inhibitor from the marine sponge Stylissa massa |
193202-57-2 |
DCC4862 |
Spongosine
Pivotal intercellular signal transmitter |
24723-77-1 |
DCC4863 |
Spop-in-6lc
Novel SPOP inhibitor, suppressing the viability and inhibiting the colony formation of ccRCC cell lines driven by cytoplasmic SPOP |
2136270-56-7 |
DCC4864 |
Spt-in-1
Novel potent serine palmitoyl transferase (SPT) inhibitor |
1933533-18-6 |
DCC4865 |
Sptssb-binder-18
Novel potent and selective binder of small subunit B of the serine palmitoyltransferase complex (SPTSSB) |
|
DCC4866 |
Spu-106
Novel specific PAK4 inhibitor, effectively inhibiting the invasion of SGC7901 cells without cytotoxicity, regulating the PAK4/LIMK1/cofilin and PAK4/SCG10 signaling pathways |
713080-84-3 |
DCC4867 |
Sr-01000634273-1
Novel inhibitor of the in vivo aggregation of |
882277-05-6 |
DCC4868 |
Sr10098
Novel NR4A nuclear receptor modulator |
850705-30-5 |
DCC4869 |
Sr10658
Novel NR4A nuclear receptor modulator |
|
DCC4870 |
Sr142948a
Selective neurotensin antagonist |
184162-64-9 |
DCC4871 |
Sr-17398 Hydrochloride
Novel Unc-51-Like Kinase 1 (ULK1) |
1585928-95-5 |
DCC4872 |
Sr2067
Novel partial agonist of PPARgamma |
|
DCC4873 |
Sr24237
Novel NR4A nuclear receptor modulator |
1167623-24-6 |
DCC4874 |
Sr-3737
Potent inhibitor of both JNK3 and p38 |
1164153-37-0 |
DCC4875 |
Sr-4326
Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3) |
1164153-25-6 |
DCC4876 |
Sr-43845
Novel renin inhibitor |
114037-60-4 |
DCC4877 |
Sr-58611a
The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents |
121524-09-2 |
DCC4878 |
Sr8185
Novel Selective TBK1/IKK dual inhibitor with anticancer potency |
|
DCC4879 |
Srctide
Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR) |
|
DCC4880 |
Srebp-in-dhg
Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK) |
|
DCC4881 |
Sri-22138
Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist |
|
DCC4882 |
Sri-29132
Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons. |
1482305-44-1 |
DCC4883 |
Sri-31040
Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding |
1928715-72-3 |
DCC4884 |
Sri-35241
Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv) |
2307429-54-3 |
DCC4885 |
Sri-36160
Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells |
2085682-66-0 |
DCC4886 |
Sri-37683
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4887 |
Sri-37684
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4888 |
Sri-39067
Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice |
|
DCC4889 |
Srt3025
Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss |
1231952-55-8 |
DCC4890 |
Srt3025 Hydrochloride
Novel potent SIRT1 activator |
2070015-26-6 |
DCC4891 |
Srt3190 (2s,3r)
Novel selective CXCR2 antagonist |
1204707-73-2 |
DCC4892 |
Srta-in-i
Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA) |
|
DCC4893 |
Ss1020
Novel antiestrogen, lacking estrogenic and genotoxic actions |
|
DCC4894 |
SS-amyloid-in-7l
Potent ß-amyloid aggregation inhibitor; Antioxidant |
|
DCC4895 |
SS-carboline-1-carboxylic Acid
Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO) |
26052-96-0 |
DCC4896 |
SS-cit
Non-selective potent dopamine reuptake inhibitor |
135416-43-2 |
DCC4897 |
SS-cit Tartrate
Non-selective potent dopamine reuptake inhibitor |
133647-95-7 |
DCC4898 |
SS-elemene
Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin |
33880-83-0 |
DCC4899 |
SS-hydroxymethyl Chalcone
The first selective inhibitor of Histone Deacetylase 2 (HDAC2) |
1613310-15-8 |
DCC4900 |
Ssj-183
Novel antimalarial agent |
1187533-34-1 |
DCC4901 |
SS-lysine
Elongation factor P (EF-P) fuction modifier |
4299-56-3 |
DCC4902 |
Ssm3 Tfa Salt
Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro. |
922732-52-3 |
DCC4903 |
SS-nf-atra
Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway |
|
DCC4904 |
SS-nf-jq1
Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity |
|
DCC4905 |
SS-nicotinamide Adenine Dinucleotide, Reduced Disodium
Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly |
606-68-8 |
DCC4906 |
Ssr126768a
Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor |
785048-28-4 |
DCC4907 |
Ssr180575
Featured
SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action. |
220448-02-2 |
DCC4908 |
SS-thujaplicinol
Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) |
4356-35-8 |
DCC4909 |
Sstr3-agonist-5c
Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist |
|
DCC4910 |
Sstr3-antagonist-3a
Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay |
|
DCC4911 |
Sstr5a
Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner |
|
DCC4912 |
St026567
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
5067-25-4 |
DCC4913 |
St029248
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
96-69-5 |
DCC4914 |
St056083
Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro |
299419-24-2 |
DCC4915 |
St101036
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
1018143-39-9 |
DCC4916 |
st-1032
Novel histamine H3 receptor ligand |
|
DCC4917 |
St1237
Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor |
1380593-17-8 |
DCC4918 |
St-161
Antiviral agent against LASV and a number of other viruses in the Arenaviridae family |
|
DCC4919 |
St-1703
Novel histamine H3 receptor ligand |
|
DCC4920 |
St-1892
Novel highly potent and soluble partial FXR agonist |
1409411-32-0 |
DCC4921 |
St-198
Seletive dopamine D3 receptors |
854924-64-4 |
DCC4922 |
St-1992
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
DCC4923 |
St-2001
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
DCC4924 |
St-2262
Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
DCC4925 |
St4070
Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
1186236-75-8 |
DCC4926 |
St7710aa1
Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
1542067-20-8 |
DCC4927 |
Sta-9584
Novel tubulin-binding vascular disrupting agent (VDA) |
906481-23-0 |
DCC4928 |
Stad-2
Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
1542100-77-5 |
DCC4929 |
Stalobacin I
Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
DCC4930 |
Stanozolol [10418-03-8]
Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
10418-03-8 |
DCC4931 |
Stat3 -in-11
Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
DCC4932 |
stat3 Inhibitor 6
Novel inhibitor of STAT3 signaling pathway |
665014-97-1 |
DCC4933 |
Stat3-in-13r
Novel inhibitor of STAT3, targeting SH2 domain |
|
DCC4934 |
Stat3-in-3
Novel potent and selective inhibitor of STAT3 |
2361304-26-7 |
DCC4935 |
Stat3-in-a69
Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
1164546-70-6 |
DCC4936 |
Stat3-in-b9
Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145 |
825611-06-1 |
DCC4937 |
Stat5a-in-27
Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t |
|
DCC4938 |
Stat5b-in-6a
Highly Potent and Selective Inhibitor of the Transcription Factor STAT5b |
|
DCC4939 |
Stemazole
Novel human stem/progenitor cells proliferation activator, promoting survival and preserving stemness in human embryonic stem cells |
317337-07-8 |
DCC4940 |
Sterigmatocystin
Natural inducer of G1 arrest in primary human esophageal epithelial cells but G2 arrest in immortalized cells |
10048-13-2 |
DCC4941 |
Stf-038533
Novel inhibitor of expression from canonical CREB response element-containing promoters |
423744-59-6 |
DCC4942 |
Stg -001
Novel RBP4 antagonist for treatment of Stargardt disease |
|
DCC4943 |
Stictic Acid
Natural anti-feline infectious peritonitis virus (FIPV) agent, specifically targeting the 3CLpro of FIPV and inhibiting its replication |
549-06-4 |
DCC4944 |
Sting Agonist 11
Novel non-nucleotide STING agonist, demonstrating antitumor activity when dosed intratumorally in a syngeneic mouse model |
|
DCC4945 |
Sting Inhibitor C-171
Novel covalent antagonist of hsSTING |
|
DCC4946 |
Stk-15
Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
844651-66-7 |
DCC4947 |
Stk-22
Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
843629-43-6 |
DCC4948 |
Stk295900
Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay |
4402-17-9 |
DCC4949 |
Stk508411
Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18) |
664968-32-5 |
DCC4950 |
Stk630921
Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA) |
1033850-63-3 |
DCC4951 |
Stk683963
Novel activator of cellular ATG4B activity |
370073-65-7 |
DCC4952 |
Stock1n-65837
Potent natural modulator of human Toll-like receptor 7 (TLR7) |
|
DCC4953 |
Streptolidine
Metablite of the Streptomyces antibiotics streptothricin and streptolin |
29307-61-7 |
DCC4954 |
Streptozocin
Antibiotic, being used as an antineoplastic agent and to induce diabetes in experimental animals |
18883-66-4 |
DCC4955 |
Sts-e412
The first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor |
1609980-39-3 |
DCC4956 |
Sts-e424
Novel agonist of the tissue-protective erythropoietin (EPO) receptor, increasing FXN expression and EPOR phosphorylation |
|
DCC4957 |
Stx-2622
Inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) |
37075-05-1 |
DCC4958 |
Stx2845
Novel Nonsteroidal Inhibitor of Carbonic Anhydrase IX |
1623785-66-9 |
DCC4959 |
Su0383
Novel dual Inhibitor of repair enzymes 8-oxoguanine DNA glycosylase (OGG1) and human MutT Homolog 1 (NUDT1 or MTH1), increasing sensitivity of tumor cells to oxidative stress |
|
DCC4960 |
Su11272
Novel potent c-MET inhibitor |
669764-16-3 |
DCC4961 |
Su11606
Potent c-MET inhibitor |
669764-17-4 |
DCC4962 |
Su11652
Sunitinib analog, acting as a potential inhibitor for nucleoside diphosphate kinase (NDK) from Leishmania major (LmNDK) |
326914-10-7 |
DCC4963 |
Su-200
Agonist of TRPV1 |
184003-14-3 |
DCC4964 |
Su9518
Novel potent and selective inhibitor of the cellular PDGF receptor kinase and PDGF receptor-induced cell proliferation |
251356-32-8 |